文献速递乳腺癌

英国乳腺癌全基因组数据与死亡统计关联的临床潜力:回顾性分析

Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis.
PubMed 文献 · Lancet Oncol · 2025-10-07

该回顾性分析纳入100kGP项目中2445例乳腺癌肿瘤(2403例患者),将全基因组测序(WGS)与死亡数据关联,评估其预后价值。

要点

  • 结构变异负荷、APOBEC签名和TP53驱动突变独立预后于ER阳性/HER2阴性乳腺癌。
  • 提出两步模型:先识别靶向治疗候选者,再对无特征者用基因组特征增强预后判断。

核心结论

  • 乳腺癌基因组富含预测和预后价值,WGS可补充现有临床措施并识别靶向治疗候选者。

研究设计与样本

  • integrative回顾性分析,纳入100kGP中2012-2018年13个中心收集的2445例乳腺癌肿瘤(2403例患者),2208例(90%)关联临床数据,1188例获取死亡数据。
  • 对肿瘤和匹配正常DNA进行高深度WGS,分析驱动突变、突变签名及HRD、MMR缺陷、TMB的复合算法评分。
  • 用三个独立队列共1803例乳腺癌患者验证部分发现;对I-III期ER阳性/HER2阴性患者以癌症特异性死亡为终点(约5年随访)进行单变量和多变量Cox回归。

主要发现

  • 开发了ER阳性/HER2阴性乳腺癌预后工具,可识别需加强干预或降阶梯治疗的患者,并在独立SCAN-B数据集中验证框架。

临床怎么用

  • 建议两步模型:首先用高度个体化基因组标记识别靶向治疗或临床试验候选者。
  • 对无此类特征的患者,将基因组特征与现有临床决策因素结合以增强预后判断。

局限性

  • 为回顾性分析,仅1188例患者获取死亡数据。
  • 预后分析限于I-III期ER阳性/HER2阴性乳腺癌,随访约5年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Breast cancer is the most frequently diagnosed cancer in women. Survival is generally considered favourable, yet some patients remain at risk of early death. We aimed to assess whether comprehensive whole-genome sequencing (WGS) linked to mortality data could add prognostic value to existing clinical measures and identify patients who might respond to targeted therapeutics. METHODS: In this integrative, retrospective analysis, we analysed 2445 breast cancer tumours (any stage and molecular subtype) collected from 2403 patients recruited through 13 National Health Service Genomic Medicine Centres or hospitals in England affiliated to the 100 000 Genomes Project (100kGP) between 2012 and 2018. We linked 2208 (90%) cases with clinical data; mortality data were obtained for 1188 patients. Following high-depth WGS of tumour and matched normal DNA, we performed comprehensive WGS profiling seeking driver mutations, mutational signatures, and compound algorithmic scores for homologous recombination repair deficiency (HRD), mismatch repair deficiency, and tumour mutational burden. Data from 1803 additional patients with breast cancer from three independent cohorts were used to validate various findings. To evaluate the prognostic value of WGS features, we performed univariable and multivariable Cox regression on data from patients with stage I-III, ER-positive, HER2-negative breast cancer with a cancer-specific mortality endpoint (around 5-year follow-up). FINDINGS: Among 2445 tumours in the 100kGP breast cancer cohort, we observed genomic characteristics with immediate personalised medicine potential in 656 (26·8%), including features reporting HRD (298 [12·2%] total cases and 76 [6·3%] ER-positive, HER2-negative cases), highly individualised driver events, mutations underpinning resistance to endocrine therapy, and mutational signatures indicating therapeutic vulnerabilities. 373 (15·2%) cases had WGS features with potential for translational research, including compromised base excision repair and non-homologous end-joining dependency. Structural variation burden (hazard ratio 3·9 [95 CI% 2·4-6·2]; p<0·0001), high levels of APOBEC signatures (2·5 [1·6-4·1]; p<0·0001), and TP53 drivers (3·9 [2·4-6·2]; p<0·0001) were independently prognostic of customary clinical measures (age at diagnosis, stage, and grade) in patients with ER-positive, HER2-negative breast cancer. We developed a prognosticator for ER-positive, HER2-negative breast cancer capable of identifying patients who require either increased intervention or therapy de-escalation, validating the framework in the independent Swedish Cancerome Analysis Network-Breast (SCAN-B) dataset. INTERPRETATION: We show that breast cancer genomes are rich in predictive and prognostic value. We propose a two-step model for effective clinical application. First, the identification of candidates for targeted therapies or clinical trials using highly individualised genomic markers. Second, for patients without such features, the implementation of enhanced prognostication using genomic features alongside existing clinical decision-making factors. FUNDING: National Institute of Health Research, Breast Cancer Research Foundation, Dr Josef Steiner Cancer Research Award 2019, Basser Gray Prime Award 2020, Cancer Research UK, Sir Jeffrey Cheah Early Career Fellowship, the Mats Paulsson Foundation, the Fru Berta Kamprads Foundation, and the Swedish Research Council.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Black D, Davies HR, Koh GCC, et al. Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis. Lancet Oncol. 2025. PMID: 41072453. doi:10.1016/S1470-2045(25)00400-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。